As you read about in Chapter 2, the race to develop a COVID-19 vaccine was a historic and highly competitive effort driven by the urgent need to control the global pandemic. One critical factor that accelerated the COVID-19 vaccine development was the commitment of the U.S. Government, under Operation Warp Speed (OWS), to purchase and distribute the vaccine to as much of the population as possible. This guarantee helped to incentivize investors to fund companies to develop vaccines. OWS also directly provided billions of dollars in funding to support vaccine research, development, and manufacturing.
To illustrate how important forward contracts were to incentivizing the development of COVID vaccines, Pfizer did not accept any government funding for its development program but did enter into a forward contract. Moderna accepted both the forward contract and funding for R&D and manufacturing expansion.
By offering the certainty of a forward contract to purchase vaccine doses at a pre-specified price, a contract that Moderna accepted, the U.S. Government significantly reduced the financial risk for companies and their investors.
Normally, developing a new vaccine involves significant uncertainty and financial risk, as companies must invest heavily in research and development with no guarantee of success or sufficient market demand. However, the government’s commitment to purchase and administer the vaccines eliminated much of this uncertainty, allowing companies to focus on rapid development and scaling up production.
Even if the pandemic somehow resolved or else burned through the population too quickly for the vaccines to be helpful, the companies knew that they would get some revenue/profit as long as they successfully developed and produced the vaccines.
This assurance of substantial revenues/profits allowed companies to confidently allocate resources, invest in large-scale manufacturing, and expedite clinical trials. OWS also enabled faster regulatory approvals, and the government took on most of the burden of distribution.
The result was an unprecedented timeline of vaccine development and public distribution, with vaccines reaching the market in less than a year---a feat previously considered nearly impossible.
Furthermore, the guaranteed purchase agreements meant that Moderna and Pfizer did not have to worry about negotiating prices with multiple insurers or reimbursement challenges. Instead, they received direct payments from the government, ensuring a steady and predictable revenue stream. This model not only accelerated vaccine availability but also highlighted the potential benefits of public-private partnerships in addressing global health crises.
Overall, the U.S. Government’s financial backing and commitment to widespread vaccine distribution were pivotal in the rapid development and deployment of COVID-19 vaccines, demonstrating the effectiveness of robust public-sector support in overcoming significant market and logistical challenges.
Once the pandemic itself ended and COVID became an endemic virus, plaguing us in waves like other respiratory viruses do, the government no longer offered companies forward contracts and let the market take over. The vaccine manufacturers now look to the market for signs of how many doses they would likely be able to sell based on varying demand. Other companies now working on COVID vaccines are no longer incentivized by forward contracts but merely the usual prospect of winning some share of the market by competing on product characteristics (e.g., better tolerability) and price.